Annual Meeting 2019 - Hepatocellular Carcinoma

Dr. James Harding (Memorial Sloan Kettering) is a board-certified medical oncologist specializes in caring for people with liver cancer, gallbladder cancer, and bile duct cancer, as well as other gastrointestinal cancers. In this week's episode, he discusses a new checkpoint inhibitor with monoclonal antibodies to programmed death receptor 1 (PD-1) for patients with Hepatocellular Carcinoma (HCC). He presents a clinical case and to highlight several aspects of immunotherapy for liver cancer.